Literature DB >> 11156563

Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.

C Blandizzi1, B De Paolis , R Colucci, G Lazzeri, F Baschiera, M Del Tacca.   

Abstract

1. This study investigates the mechanisms accounting for the adverse cholinergic effects of the antitumour drug irinotecan. The activity of irinotecan and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), was assayed in models suitable for pharmacological studies on cholinergic system. 2. Irinotecan moderately inhibited human or electric eel acetylcholinesterase activity, SN-38 had no effect, whereas physostigmine blocked both the enzymes with high potency and efficacy. 3. Irinotecan and SN-38 did not affect spontaneous or electrically-induced contractile activity of human colonic muscle. Acetylcholine and dimethylphenylpiperazinium (DMPP) caused phasic contractions or relaxations, respectively. Physostigmine enhanced the motor responses elicited by electrical stimulation. 4. Although irinotecan and SN-38 did not modify the basal contractile activity of guinea-pig ileum longitudinal muscle strips, irinotecan 100 microM moderately enhanced cholinergic twitch contractions. Acetylcholine or DMPP caused phasic contractions, whereas physostigmine enhanced the twitch responses. Electrically-induced [(3)H]-acetylcholine release was reduced by irinotecan (100 microM) or physostigmine (0.1 microM). 5. Intravenous irinotecan stimulated gastric acid secretion in rats, but no effects were obtained with SN-38, physostigmine or i.c.v. irinotecan. Hypersecretion induced by irinotecan was partly prevented by ondansetron, and unaffected by capsazepine. In the presence of atropine, vagotomy and systemic or vagal ablation of capsaicin-sensitive afferent fibres, irinotecan did not stimulate gastric secretion. 6. The present results indicate that irinotecan and SN-38 do not act as specific acetylcholinesterase blockers or acetylcholine receptor agonists. It is rather suggested that irinotecan promotes a parasympathetic discharge to peripheral organs, mediated by capsaicin-sensitive vagal afferent fibres, and that serotonin 5-HT(3) receptors are implicated in the genesis of vago-vagal reflex triggered by irinotecan.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156563      PMCID: PMC1572526          DOI: 10.1038/sj.bjp.0703766

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Effects of four cholinesterase inhibitors on the response of the guinea-pig isolated ileum to transmural electrical stimulation.

Authors:  B Cox; G Stobart
Journal:  J Pharm Pharmacol       Date:  1972-10       Impact factor: 3.765

2.  Presynaptic inhibitory effect of Met-enkephalin on [14C] acetylcholine release from the myenteric plexus and its interaction with muscarinic negative feedback inhibition.

Authors:  E S Vizi; K Ono; V Adam-Vizi; D Duncalf; F F Földes
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

3.  A pharmacological comparison of organophosphorus and carbamate anti-cholinesterase agents on guinea pig ileum.

Authors:  S Yamada; M Katsuoka; H Okudaira; E Hayashi
Journal:  Toxicol Appl Pharmacol       Date:  1982-06-15       Impact factor: 4.219

4.  Capsaicin-sensitive vagal afferent fibers and stimulation of gastric acid secretion in anesthetized rats.

Authors:  H E Raybould; Y Taché
Journal:  Eur J Pharmacol       Date:  1989-08-22       Impact factor: 4.432

5.  Effect of ascorbate on the contractile response induced by DMPP in guinea-pig ileal longitudinal muscle strip.

Authors:  E Hayashi; K Shinozuka; T Maeda; M Takeda
Journal:  Eur J Pharmacol       Date:  1983-05-06       Impact factor: 4.432

Review 6.  Suitability of urethane anesthesia for physiopharmacological investigations. Part 3: Other systems and conclusions.

Authors:  C A Maggi; A Meli
Journal:  Experientia       Date:  1986-05-15

7.  A PRELIMINARY INVESTIGATION OF THE PHARMACOLOGY OF THE HUMAN ISOLATED TAENIA COLI PREPARATION.

Authors:  A BUCKNELL; B WHITNEY
Journal:  Br J Pharmacol Chemother       Date:  1964-08

8.  Evidence that cholinergic axon terminals are equipped with both muscarinic and adenosine receptors.

Authors:  G T Somogyi; E S Vizi
Journal:  Brain Res Bull       Date:  1988-10       Impact factor: 4.077

9.  Effects of cholinergic blockade, adrenergic blockade and sympathetic denervation on gastrointestinal myoelectric activity in guinea pig.

Authors:  J J Galligan; J B Furness; M Costa
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

10.  Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase.

Authors:  Q S Yu; J R Atack; S I Rapoport; A Brossi
Journal:  FEBS Lett       Date:  1988-07-04       Impact factor: 4.124

View more
  13 in total

1.  Irinotecan-induced dysarthria: an insight into its pathogenesis?

Authors:  Jesus A Gomez; Ines Sanchez; Jose A Ramirez
Journal:  Gastrointest Cancer Res       Date:  2008-07

2.  Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice.

Authors:  M Fornai; C Blandizzi; R Colucci; L Antonioli; N Bernardini; C Segnani; B Baragatti; S Barogi; P Berti; R Spisni; M Del Tacca
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).

Authors:  H M Dodds; L P Rivory
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  Redesigning the T-probe for mass spectrometry analysis of online lysis of non-adherent single cells.

Authors:  Yanlin Zhu; Renmeng Liu; Zhibo Yang
Journal:  Anal Chim Acta       Date:  2019-07-31       Impact factor: 6.558

5.  Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.

Authors:  Changsuk Moon; Weiqiang Zhang; Aixia Ren; Kavisha Arora; Chandrima Sinha; Sunitha Yarlagadda; Koryse Woodrooffe; John D Schuetz; Koteswara Rao Valasani; Hugo R de Jonge; Shiva Kumar Shanmukhappa; Mohamed Tarek M Shata; Randal K Buddington; Kaushik Parthasarathi; Anjaparavanda P Naren
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

6.  Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.

Authors:  Jianping Xu; Jing Huang; Yun Liu; Bo Zhang; Xingyuan Wang; Jialin Tang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-24       Impact factor: 3.333

7.  Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.

Authors:  T C Chang; H S Shiah; C H Yang; K H Yeh; A L Cheng; B N Shen; Y W Wang; C G Yeh; N J Chiang; J Y Chang; L T Chen
Journal:  Cancer Chemother Pharmacol       Date:  2015-01-11       Impact factor: 3.333

8.  Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

Authors:  Hiro Takahashi; Kimie Sai; Yoshiro Saito; Nahoko Kaniwa; Yasuhiro Matsumura; Tetsuya Hamaguchi; Yasuhiro Shimada; Atsushi Ohtsu; Takayuki Yoshino; Toshihiko Doi; Haruhiro Okuda; Risa Ichinohe; Anna Takahashi; Ayano Doi; Yoko Odaka; Misuzu Okuyama; Nagahiro Saijo; Jun-ichi Sawada; Hiromi Sakamoto; Teruhiko Yoshida
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

9.  Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience.

Authors:  Ali Elbeddini; Naushin Hooda; Mohamed Gazarin; Penny Webster; Jackie McMillan
Journal:  Am J Case Rep       Date:  2020-06-28

10.  A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients.

Authors:  Tetsuya Hamaguchi; Akihito Tsuji; Kensei Yamaguchi; Koji Takeda; Hiroyuki Uetake; Taito Esaki; Kenji Amagai; Daisuke Sakai; Hideo Baba; Masami Kimura; Yasuhiro Matsumura; Tetsuji Tsukamoto
Journal:  Cancer Chemother Pharmacol       Date:  2018-10-04       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.